Keyphrases
MD Anderson Cancer Center
100%
Patients with Cancer
100%
Viral Hepatitis
100%
Center Experience
100%
Immune Checkpoint Inhibitors
100%
Hepatitis
33%
Therapeutic Potential
16%
Clinical Benefit
16%
Incidence Rate
16%
Adverse Events
16%
Cancer Treatment
16%
Follow-up Time
16%
Clinical Trials
16%
Am(III)
16%
Hepatitis B
16%
Hepatitis C
16%
Safety Profile
16%
Safety Concerns
16%
Antiretroviral Therapy
16%
Acceptable Safety
16%
Immune-related Adverse Events
16%
Advanced Liver Disease
16%
Immune Checkpoint Inhibitor Therapy
16%
Immune Checkpoint Inhibitor Treatment
16%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Virus Hepatitis
100%
Immune Checkpoint Inhibitor
100%
Adverse Event
25%
Retrospective Study
12%
Clinical Trial
12%
Hepatitis B Virus
12%
Hepatitis C
12%
Hepatitis B
12%
Liver Disease
12%
Antiviral Therapy
12%